Delayed orthostatic hypotension in Parkinson's disease and in the general ageing population
- PMID: 40622385
- PMCID: PMC12647057
- DOI: 10.1093/ageing/afaf187
Delayed orthostatic hypotension in Parkinson's disease and in the general ageing population
Abstract
Objective: Delayed orthostatic hypotension (dOH) is defined by a sustained blood pressure (BP) fall ≥20/10 mmHg occurring beyond 3 minutes in the upright position, whose clinical relevance is yet undetermined. We investigated frequency, associated features and treatment strategies of dOH in Parkinson's Disease (PD) and ageing individuals with history of syncope or orthostatic intolerance.
Methods: We retrospectively studied 213 individuals with PD and 213 age-matched individuals without parkinsonism referred for tilt-table testing to the Innsbruck and Florence Dysautonomia centres. In both cohorts, we reviewed the medical records of the 6 months before testing for history of syncope and falls, and of the 6 months afterwards for the recommended dOH treatment and clinical outcome.
Results: dOH was twice as frequent in PD than in ageing individuals [18% versus 9%; OR = 2.9 (95 CI.: 1.3-6.5), P = .007]. Upon prolonged head-up tilt, PD individuals showed a more severe systolic BP fall (P < .001). PD individuals with history of syncope also exhibited a sustained systolic BP fall from the 3rd minute of head-up tilt onward compared to those without (P = .014). Both non-pharmacological and pharmacological OH treatment strategies were associated with symptomatic improvement at follow-up.
Conclusions: In PD individuals referred to tertiary settings, tilt-table testing more frequently disclosed dOH compared to age-matched individuals without parkinsonism. In PD, dOH is mainly driven by a progressive orthostatic systolic BP fall, increasing the risk of syncope. Given its prevalence and the potential for effective treatment, dOH should be actively screened for in clinical practice.
Keywords: Parkinson’s disease; ageing population; delayed orthostatic hypotension; falls; older people; syncope.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
J-P.N. reports Honoria from the Austrian Autonomic Society, the Austrian Parkinson Society, outside of the present work.
K.S. KS reports honoraria from the International Parkinson and Movement Disorders Society, grants from the FWF Austrian Science Fund, the Michael J. Fox Foundation, and the International Parkinson and Movement Disorder Society, as well as personal fees from Teva, UCB, Lundbeck, AOP Orphan Pharmaceuticals AG, AbbVie, Roche, and Grünenthal, outside the submitted work.
W.P. reports personal fees from Alterity, AbbVie, AC-Immune, AstraZeneca, BIAL, Biogen, Britannia, Lilly, Lundbeck, Neuroderm, Roche, Takeda, Teva, UCB and Zambon in relation to consultancy around clinical drug development programmes for PD and MSA, outside of the present work.
M.R. reports speaker fees from Boston Scientific.
A.F. reports royalties from Springer Verlag, speaker fees and honoraria from Bial, CNSystems, Elsevier, Theravance Biopharma, Medtronic, Sanofi, Austrian Autonomic Society, Austrian Neurology Society, International Parkinson Disease and Movement Disorders Society, Elsevier and research grants from the FWF-Austrian Science Fund, Medical University of Innsbruck, Mission MSA and Dr Johannes and Hertha Tuba Foundation, outside of the present work.
Figures
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
